Anne-Sophie de Faucigny
Public Communications Contact chez GETLINK SE
Postes actifs de Anne-Sophie de Faucigny
Sociétés | Poste | Début | Fin |
---|---|---|---|
GETLINK SE | Public Communications Contact | 01/10/2022 | - |
Historique de carrière de Anne-Sophie de Faucigny
Anciens postes connus de Anne-Sophie de Faucigny
Sociétés | Poste | Début | Fin |
---|---|---|---|
Yposkesi
Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Directeur/Membre du Conseil | 01/01/2018 | 01/01/2021 |
Formation de Anne-Sophie de Faucigny
Institut d’Études Politiques de Toulouse | Graduate Degree |
Statistiques
Internationale
France | 4 |
Opérationnelle
Director/Board Member | 1 |
Public Communications Contact | 1 |
Graduate Degree | 1 |
Sectorielle
Health Technology | 2 |
Transportation | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
GETLINK SE | Transportation |
Entreprise privées | 1 |
---|---|
Yposkesi
Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Health Technology |
- Bourse
- Insiders
- Anne-Sophie de Faucigny
- Expérience